359 related articles for article (PubMed ID: 33028341)
1. Profiling pro-neural to mesenchymal transition identifies a lncRNA signature in glioma.
Liang Q; Guan G; Li X; Wei C; Wu J; Cheng P; Wu A; Cheng W
J Transl Med; 2020 Oct; 18(1):378. PubMed ID: 33028341
[TBL] [Abstract][Full Text] [Related]
2. Identification of an epithelial-mesenchymal transition related long non-coding RNA (LncRNA) signature in Glioma.
Tao C; Luo H; Chen L; Li J; Zhu X; Huang K
Bioengineered; 2021 Dec; 12(1):4016-4031. PubMed ID: 34288803
[TBL] [Abstract][Full Text] [Related]
3. A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients.
He Y; Ye Y; Tian W; Qiu H
Front Cell Dev Biol; 2021; 9():788451. PubMed ID: 34950662
[No Abstract] [Full Text] [Related]
4. Integrative analysis of multi-omics data reveals a pseudouridine-related lncRNA signature for prediction of glioma prognosis and chemoradiotherapy sensitivity.
Yang Y; Wang F; Teng H; Zhang C; Zhang Y; Chen P; Li Q; Kan X; Chen Z; Wang Z; Yu Y
Comput Biol Med; 2023 Nov; 166():107428. PubMed ID: 37748218
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
6. An immune-related lncRNA signature for patients with anaplastic gliomas.
Wang W; Zhao Z; Yang F; Wang H; Wu F; Liang T; Yan X; Li J; Lan Q; Wang J; Zhao J
J Neurooncol; 2018 Jan; 136(2):263-271. PubMed ID: 29170907
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of a five-lncRNA prognostic signature related to Glioma using bioinformatics analysis.
Zhang C; Liu H; Xu P; Tan Y; Xu Y; Wang L; Liu B; Chen Q; Tian D
BMC Cancer; 2021 Mar; 21(1):251. PubMed ID: 33750353
[TBL] [Abstract][Full Text] [Related]
8. Analysis of long non-coding RNAs in glioblastoma for prognosis prediction using weighted gene co-expression network analysis, Cox regression, and L1-LASSO penalization.
Liang R; Zhi Y; Zheng G; Zhang B; Zhu H; Wang M
Onco Targets Ther; 2019; 12():157-168. PubMed ID: 30613154
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of a Novel Stemness-Index-Related Long Noncoding RNA Signature for Breast Cancer Based on Weighted Gene Co-Expression Network Analysis.
Qian D; Qian C; Ye B; Xu M; Wu D; Li J; Li D; Yu B; Tao Y
Front Genet; 2022; 13():760514. PubMed ID: 35273635
[No Abstract] [Full Text] [Related]
10. Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma.
Su Y; Zhang T; Tang J; Zhang L; Fan S; Zhou J; Liang C
Front Oncol; 2021; 11():640150. PubMed ID: 33869028
[TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of an Energy Metabolism-Related lncRNA-mRNA Signature for Lower-Grade Glioma.
Zhao J; Wang L; Wei B
Biomed Res Int; 2020; 2020():3708231. PubMed ID: 32802843
[TBL] [Abstract][Full Text] [Related]
12. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
Fan CN; Ma L; Liu N
J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
[TBL] [Abstract][Full Text] [Related]
13. An Immune-Related lncRNA Signature to Predict Survival In Glioma Patients.
Xia P; Li Q; Wu G; Huang Y
Cell Mol Neurobiol; 2021 Mar; 41(2):365-375. PubMed ID: 32410107
[TBL] [Abstract][Full Text] [Related]
14. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma.
Li R; Chen H; Li C; Qi Y; Zhao K; Wang J; You C; Huang H
BMC Bioinformatics; 2023 Jul; 24(1):274. PubMed ID: 37403043
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of oxidative stress-related lncRNA signatures in glioma reveals the discrepancy of prognostic and immune infiltration.
Shi Z; Wu Y; Zhuo Q; Zuo Y; Lin J; Shi H; Zhou H; Xu Z
Sci Rep; 2023 May; 13(1):7731. PubMed ID: 37173373
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
18. An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme.
Zhou M; Zhang Z; Zhao H; Bao S; Cheng L; Sun J
Mol Neurobiol; 2018 May; 55(5):3684-3697. PubMed ID: 28527107
[TBL] [Abstract][Full Text] [Related]
19. Mutation-derived, genomic instability-associated lncRNAs are prognostic markers in gliomas.
Li S; Chen Y; Guo Y; Xu J; Wang X; Ning W; Ma L; Qu Y; Zhang M; Zhang H
PeerJ; 2023; 11():e15810. PubMed ID: 37547724
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of an Mesenchymal-Related Long Non-Coding RNA Prognostic Model in Glioma.
Huang K; Yue X; Zheng Y; Zhang Z; Cheng M; Li L; Chen Z; Yang Z; Bian E; Zhao B
Front Oncol; 2021; 11():726745. PubMed ID: 34540695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
